Can You Take 5-Amino-1MQ With Tirzepatide or Semaglutide?

The medications this page covers:

Every price is all-in, covering medication, physician review, refill management and shipping, with no membership fee. The GLP-1 prices are "from" prices because the vials are dose-specific. Compounded medications are not FDA approved.

What tirzepatide does

Tirzepatide is a single peptide that activates two incretin receptors, GIP and GLP-1. It acts on appetite centres in the brain, slows gastric emptying and changes insulin and glucagon signalling, and the weight change reported in its trials follows from people eating less over a long period. Semaglutide does the same through one receptor, GLP-1. The full reference is what is tirzepatide.

What 5-Amino-1MQ is described to do

5-Amino-1MQ is a small molecule, not a peptide, developed by a medicinal chemistry group at the University of Texas Medical Branch. It is designed to inhibit nicotinamide N-methyltransferase (NNMT), an enzyme that takes nicotinamide, the form of vitamin B3 cells recycle into NAD+, and attaches a methyl group to it so it is excreted instead. A 2014 paper in Nature reported NNMT expression rising in the fat and liver of obese mice, and knocking the enzyme down protected them against diet-induced obesity. In cultured fat cells, a 2018 paper in Biochemical Pharmacology reported NNMT inhibitors raising intracellular NAD+ and suppressing the building of new fat.

It is not a GLP-1 medication, a stimulant or a thermogenic, and it does not contain NAD+. The 2018 mouse work reported total food intake unchanged in treated animals, so no appetite effect is expected. The full reference is what is 5-Amino-1MQ, and why it is not a peptide is in is 5-Amino-1MQ a peptide.

FUSION puts 5-Amino-1MQ in one vial with BPC-157, MOTS-c and tesamorelin, and it is positioned for use with or without a GLP-1.

In a blend, the considerations are those of every ingredient. Tesamorelin raises growth hormone and IGF-1 and reduces insulin sensitivity, while GLP-1 medications act in the other direction, so glucose is the thing a physician watches with FUSION alongside a GLP-1. MOTS-c is associated with transient jitteriness, a faster pulse or mild light-headedness after a dose, mostly early on. Prescribers using FUSION alongside a GLP-1 describe less of the gut discomfort patients associate with the GLP-1; that has not been tested in a trial. No study has tested the blend as a blend. More in what is FUSION.

They are separate injections from separate vials, each drawn with its own sterile syringe, and never mixed. Subcutaneous means into the fat layer, not the muscle; rotate between the abdomen and thigh. Both arrive as ready-to-use solutions with directions printed on the vial. The arithmetic is in 5-Amino-1MQ dosage and tirzepatide dosing chart.

Everything above applies to semaglutide. It acts at one incretin receptor where tirzepatide acts at two, but both work through appetite and gastric emptying, and 5-Amino-1MQ acts on neither. The same caveats apply: no study of the combination, no human trial of 5-Amino-1MQ, and the theoretical interaction point. The comparison of the two GLP-1 medications is in semaglutide vs tirzepatide.

1. Name the goal, not the molecule. Tell your physician what you hope to change, so they can say whether 5-Amino-1MQ, a blend or nothing extra fits.
2. List everything. Every prescription, supplement and vitamin, because of the NNMT interaction point.
3. Start one thing at a time. Avoid starting it in the same week as a GLP-1 dose step.
4. Report what happened, including nothing. With no human trial data, your reports are part of how your physician judges what is happening.

Your physician sets your directions after reviewing your intake, and every vial arrives with its directions printed on the label. The longer version is in can you take two peptides together.

5-Amino-1MQ is not an FDA-approved drug or a component of one, and has no USP monograph. It does not appear in Category 1, 2 or 3 of the FDA's list of bulk substances nominated for 503A compounding, as updated 14 May 2026, and it has never been before the Pharmacy Compounding Advisory Committee. The FDA has never published a safety-risk finding about it. No finding against it is not a finding for it; it has simply not been evaluated. It remains a compounded, prescription-only medication.

1. Complete a free online intake covering your history, every medication and supplement you take (including any GLP-1), and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares each medication to that prescription. Lot test results are published at /quality/lab-results.
4. Each ships refrigerated with ice packs, with sterile syringes, alcohol prep pads and your directions printed on the vial.
5. Your care team stays reachable for questions and side effects.

Pepti is cash-pay and does not bill insurance. Step by step: how to get 5-Amino-1MQ prescribed and how to get tirzepatide prescribed. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.